Romosozumab Treatment in Postmenopausal Women with Osteoporosis

20161,660 citationsJournal Articlebronze Open Access

Authors

Felicia Cosman · Columbia University

Daria B. Crittenden · Amgen (United States)

Jonathan D. Adachi · McMaster University

Neil Binkley · University of Wisconsin–Madison

E. J. Czerwiński · Krakow Cardiovascular Research Institute

Serge Ferrari

Lorenz C. Hofbauer · TU Dresden

Abstract

In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .).

Topics & Keywords

Bone Metabolism and Diseases Bone health and osteoporosis research Bone health and treatments

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 16, pp. 1532-1543

DOI: 10.1056/nejmoa1607948

Field-Weighted Citation Impact: 69.76

Command Palette

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Authors

Abstract

Topics & Keywords

Publication Details